FEAF
TWSE

6414 樺漢

336.50 ▲ 8.50 (2.59%) Close · 2026-11-13 · TWSE
Ask about 6414
This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.

Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.

Your risk profile
Conclusion

Mixed picture: 2 strengths against 2 watch-outs. Weigh them against your own goals.

Points to watch for a moderate profile: see the items marked above.

No model narrative: the model call failed. The structured analysis above is complete on its own.

Strengths

+ The current price implies -13.1% perpetual growth, within the 3.5% ceiling: expectations look attainable. source (Valuation) →
+ Free cash flow was positive in 2025: 8,451 NT$ million. source (Financials) →

Watch-outs

! Revenue fell -2.8% in 2025; latest quarter Q3 2026: 44.5% year on year. source (Financials) →
! Liabilities are 70.0% of total assets (Q3 2026): a heavy debt load. source (Financials) →

What to check before deciding

?Is the revenue decline temporary or structural?
?Can operating cash cover the debt if conditions tighten?

What the analysis found

+ Valuation (DCF) The current price implies -13.1% perpetual growth, within the 3.5% ceiling: expectations look attainable. source →
· Valuation vs peers P/E 13.54 is close to the Computers and peripherals median of 15.10 (55 listed peers). source →
! Growth Revenue fell -2.8% in 2025; latest quarter Q3 2026: 44.5% year on year. source →
· Profitability Return on equity 14.9% with a 2.2% net margin: moderate profitability. source →
! Debt Liabilities are 70.0% of total assets (Q3 2026): a heavy debt load. source →
+ Cash flow Free cash flow was positive in 2025: 8,451 NT$ million. source →
· Filings 3 verified alert(s); latest on 2026-11-11: 本公司董事會決議發行國內第八次無擔保轉換公司債 source →
· Filings 1 filing(s) are held or rejected and wait for human review. source →